CeQur Secures $120 Million in Funding: Innovating Mealtime Insulin Delivery with CeQur Simplicity

CeQur, a pioneering medical device company dedicated to transforming insulin delivery for individuals relying on multiple daily injections, has successfully completed a significant funding round, raising $120 million. This substantial investment will enable CeQur to further advance its innovative product, CeQur Simplicity, a wearable insulin delivery device designed for discreet and convenient bolus dosing without the need for needles. With the recent FDA 510(k) clearance granting an extension of the device's wear duration from three to four days, CeQur Simplicity now offers the capability to hold up to 200 units of rapid-acting insulin, administered in precise two-unit increments. This enhancement can potentially replace an average of twelve daily mealtime injections over the course of four days, significantly improving the quality of life for those managing diabetes. The funding will facilitate the scaling of production, support ongoing clinical studies, and accelerate the company’s market reach, enhancing accessibility to this groundbreaking technology. Headquartered in Horw, Switzerland, CeQur remains committed to empowering individuals with diabetes through innovative solutions designed to simplify their daily routines. As CeQur continues to pave the way in insulin delivery advancements, this funding signifies a crucial step towards fulfilling its mission of delivering a needle-free future for diabetes management. For more information about CeQur and its transformative product, please visit myceqursimplicity.com.